AIM ImmunoTech Inc. filings document an immuno-pharma issuer centered on Ampligen (rintatolimod) and its public-company financing, clinical and governance disclosures. Recent 8-K reports cover material agreements, Regulation FD clinical updates for the DURIPANC pancreatic cancer study, amendments to equity distribution arrangements, warrant notices, and operating and financial results.
Registration statements and related exhibits disclose rights-offering terms, Series G Convertible Preferred Stock, common stock purchase warrants, beneficial-ownership limits, warrant agency arrangements, and shelf or at-the-market equity issuance mechanics. The filings also address risk factors, shareholder-rights modifications, corporate-governance items and capital-structure changes relevant to AIM's research-and-development drug business.
AIM ImmunoTech Inc. completed a warrant exercise inducement transaction, raising approximately $3.6 million in gross proceeds. Holders agreed to exercise Existing Warrants for cash to purchase an aggregate of 7,451,920 shares of common stock at a reduced exercise price of $0.48 per share.
In return, the company issued new Class H Inducement Warrants to purchase up to 14,903,840 shares of common stock at an exercise price of $0.60 per share, exercisable for five years after the stockholder approval date. Ladenburg Thalmann & Co. Inc. acted as placement agent, receiving about $285,000 in fees, $50,000 for expenses, and about $26,000 as a management fee, plus additional placement agent warrants. All new warrants and underlying shares were issued in a private, unregistered offering under Section 4(a)(2) of the Securities Act.
AIM ImmunoTech Inc. entered into a warrant exercise inducement agreement with holders of existing warrants covering up to 8,719,928 shares of common stock. Holders agreed to exercise these warrants for cash at a reduced exercise price of $0.48 per share.
In return, the company will issue new Class H Inducement Warrants to purchase up to 17,439,856 shares of common stock at $0.60 per share, with a five-year term starting on the stockholder approval date. If all existing warrants are exercised in full, AIM ImmunoTech expects to receive approximately $4.20 million in gross proceeds for working capital and general corporate purposes.
The company engaged Ladenburg Thalmann as placement agent, agreeing to an 8.0% cash fee on aggregate gross proceeds, a 0.75% management fee, reimbursement of up to $50,000 of expenses, and issuance of placement agent warrants for up to 6% of the exercised shares. The Inducement Warrants were issued under a Section 4(a)(2) exemption and the related shares will be registered for resale after closing.
AIM ImmunoTech Inc. entered into Amendment No. 1 to its Equity Distribution Agreement with Maxim Group LLC, which serves as its exclusive sales agent for an at-the-market stock offering. The original agreement covered issuance and sale of up to $3,000,000 of common shares.
The amendment removes the limitation on the amount of shares that may be sold under the agreement, allowing additional sales under the company’s effective shelf registration statement on Form S-3 and related prospectus. AIM is also filing a new prospectus supplement to increase the number of shares that may be offered and sold through this at-the-market program.
Amid an existing shelf registration, AIM ImmunoTech, Inc. filed a prospectus supplement dated April 10, 2026 to increase the maximum aggregate offering price under its equity distribution agreement with Maxim Group LLC to $3,409,174. The supplement relies on General Instruction I.B.6 of Form S-3 and notes a public float of $10,227,521 calculated using 8,182,017 shares held by non‑affiliates at $1.25 per share (closing price on February 13, 2026).
The company states it has sold $2,288,758.60 under the instruction during the prior 12 months and is eligible to sell an additional $1,120,415. Sales, if any, may be made as “at the market offerings” through Maxim, which may receive compensation up to 3.0% of gross proceeds. The supplement affirms Maxim will be deemed an underwriter for these sales and that indemnification provisions apply.
AIM ImmunoTech Inc. reports on an extensive R&D pipeline centered on its dsRNA drug Ampligen for late-stage pancreatic cancer, other solid tumors, antivirals, ME/CFS and post-COVID conditions, plus legacy product Alferon N Injection. The company highlights promising early- and mid-stage clinical data, orphan drug designations and multiple patents supporting oncology and antiviral strategies.
At the same time, AIM discloses recurring operating losses, net cash use, a working capital deficit and a stockholders’ deficit of approximately $9,783,000 as of December 31, 2025, leading management to conclude that substantial doubt exists about its ability to continue as a going concern. AIM is also not in compliance with NYSE American stockholders’ equity requirements and faces a potential delisting if it cannot raise equity above $6,000,000 by June 11, 2026, despite having regained compliance with minimum price rules via a 1‑for‑100 reverse split in 2025.
Mitigating steps include a third‑quarter 2025 vendor settlement that forgave $3,041,000 of legal fees in exchange for $1,875,000 of payments, recorded as other income, and a January 2026 stock dividend that reset Class E and F warrant terms, reduced their exercise price to $1.439 and allowed those warrants to be reclassified from liabilities to equity, which AIM states will significantly increase stockholders’ equity. The company also signed an agreement with Thermo Fisher Scientific’s PPD clinical research business to design an anticipated Phase 3 trial of Ampligen in late‑stage pancreatic cancer, reflecting its strategic focus on this indication as its most attractive commercial opportunity.
AIM ImmunoTech Inc. CEO and President Thomas K. Equels converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock. The preferred stock position was reduced to zero, and his directly held common stock increased to 63,922 shares following the transaction.
AIM ImmunoTech Inc. director David I. Chemerow converted preferred stock into common shares. He converted 25 shares of Series G Convertible Preferred Stock into 25,000 shares of common stock through a derivative conversion at no stated cash price. A footnote explains each preferred share is convertible into 1,000 common shares, effectively valuing the conversion at $1.00 per common share. Following the conversion, he directly holds 28,441 shares of AIM ImmunoTech common stock, with no remaining Series G preferred shares reported.
AIM ImmunoTech Inc. CEO and President Thomas K. Equels reported changes in his holdings of derivative securities related to a rights offering. On March 6, 2026, he held 25 shares of Series G Convertible Preferred Stock, each with a stated value of $1,000 and convertible into 1,000 shares of common stock, issued as part of a subscription right in a rights offering. He also reported 50,000 Class G Warrants, each exercisable for one share of common stock at an exercise price of $1.00 per share, likewise issued as part of a subscription right in a rights offering. Following these transactions, he directly held 38,922 shares of common stock.
AIM ImmunoTech director David I. Chemerow reported new derivative holdings tied to a rights offering. He now holds 25 shares of Series G Convertible Preferred Stock, each with a stated value of $1,000 and convertible into 1,000 shares of common stock, issued through a subscription right in a rights offering.
He also reported 50,000 Class G Warrants, each exercisable for one share of common stock at an exercise price of $1.00, likewise issued as part of a subscription right in a rights offering. Following these transactions, he directly holds 3,441 shares of common stock, alongside the preferred shares and warrants.
AIM ImmunoTech Inc. completed a previously announced rights offering, raising approximately $1.8 million by selling 1,842 units. Each unit included one share of Series G Convertible Preferred Stock and Class G warrants.
The company created a new Series G preferred series of 12,000 shares, each with a stated value of $1,000 and initially convertible into common stock at $1.00 per share, subject to standard anti-dilution adjustments. Conversions are limited so that holders generally cannot exceed 4.99% beneficial ownership, adjustable by the holder up to 9.99%. The rights offering also issued 3,684,000 Class G warrants, each exercisable for one share of common stock at $1.00 per share for five years. The Series G preferred is non-voting (with limited exceptions), participates with common stock in dividends and liquidation on an as-converted basis, and has no mandatory redemption features.